share_log

Analyzing Rapid Micro Biosystems (NASDAQ:RPID) and Seer (NASDAQ:SEER)

Financial News Live ·  Jan 7, 2023 19:11

Rapid Micro Biosystems (NASDAQ:RPID – Get Rating) and Seer (NASDAQ:SEER – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends.

Insider & Institutional Ownership

61.0% of Rapid Micro Biosystems shares are held by institutional investors. Comparatively, 76.2% of Seer shares are held by institutional investors. 38.0% of Rapid Micro Biosystems shares are held by insiders. Comparatively, 18.0% of Seer shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Get Rapid Micro Biosystems alerts:

Valuation and Earnings

This table compares Rapid Micro Biosystems and Seer's revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Rapid Micro Biosystems $23.23 million 2.28 -$73.52 million ($1.39) -0.91
Seer $6.62 million 43.53 -$71.17 million ($1.45) -3.17
Seer has lower revenue, but higher earnings than Rapid Micro Biosystems. Seer is trading at a lower price-to-earnings ratio than Rapid Micro Biosystems, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Rapid Micro Biosystems and Seer, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rapid Micro Biosystems 0 2 0 0 2.00
Seer 1 2 0 0 1.67

Rapid Micro Biosystems presently has a consensus price target of $10.00, indicating a potential upside of 693.65%. Seer has a consensus price target of $9.83, indicating a potential upside of 113.77%. Given Rapid Micro Biosystems' stronger consensus rating and higher probable upside, equities analysts clearly believe Rapid Micro Biosystems is more favorable than Seer.

Risk & Volatility

Rapid Micro Biosystems has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. Comparatively, Seer has a beta of 1.46, meaning that its stock price is 46% more volatile than the S&P 500.

Profitability

This table compares Rapid Micro Biosystems and Seer's net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Rapid Micro Biosystems -328.18% -29.41% -26.52%
Seer -646.27% -18.80% -17.32%

Summary

Rapid Micro Biosystems beats Seer on 7 of the 13 factors compared between the two stocks.

About Rapid Micro Biosystems

(Get Rating)

Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in North America, Europe, and Asia. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and comprehensive customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides installation and verification, technical training, and support services. Its solutions are used in environmental monitoring, water testing, bioburden, and sterility release testing applications. The company was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. Rapid Micro Biosystems, Inc. was incorporated in 2006 and is headquartered in Lowell, Massachusetts.

About Seer

(Get Rating)

Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

Receive News & Ratings for Rapid Micro Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapid Micro Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment